Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases

Fig. 3

Transcriptional co-activators effectuate transcription of oncogenes in cancers of endocrine organs. (a) Several transcriptional co-activators, namely SRC, CITED2, SET7, DDX17, and ADA3 have been identified to work in association with the hormone-regulated transcription factor, estrogen receptor (ER), to promote breast cancer. Apart from ER co-regulators, several other transcriptional co-activators like MRTF, BCL9/BCL9L, EYA2, TRIM24 and YAP/TAZ promote breast cancer tumorigenesis. (b) In prostate cancer, the involvement of transcriptional co-activators CBP/p300,BCL9, PC4and ARA70 have been documented. (c) Enhanced expression of YAP/TAZ, CBP/p300, CRTC2, TRIM24, and BRD4 have been observed to be associated with ovarian cancer metastasis, therapy resistance and poor patient prognosis (d) The coordinated interaction between VGLL1 and TEAD1 promotes cervical cancer growth by mediating transcription of HPV early genes. Other transcriptional co-activators associated with cervical cancer are KMT2A, TRIM24 and TRIM28. CRPC, castrate-resistant prostate cancer; APIC, androgen-independent prostate cancer; HRPC, hormone-refractory prostate cancer; HGSC, ovarian high-grade serous carcinoma. This figure was created using BioRender (https://biorender.com/)

Back to article page